Evidence supporting the use of: Lactobacillus rhamnosus
For the health condition: Small Intestinal Bacterial Overgrowth

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Lactobacillus rhamnosus is a probiotic strain that has been investigated for its potential role in supporting or adjunctively treating Small Intestinal Bacterial Overgrowth (SIBO). The rationale for its use is primarily scientific, although the quality and consistency of evidence are limited. SIBO is characterized by an abnormal increase in the number or type of bacteria in the small intestine, often leading to digestive symptoms such as bloating, diarrhea, and malabsorption. Several studies have examined the effects of probiotics, including L. rhamnosus, on SIBO and related gastrointestinal disorders. Some small clinical trials and observational studies suggest that probiotics may help restore normal gut flora, inhibit pathogenic bacteria, reduce inflammation, and improve symptoms associated with SIBO. For example, a few studies have reported that multi-strain probiotics containing L. rhamnosus can decrease hydrogen production on breath tests and improve gastrointestinal symptoms. However, the evidence is not robust; most studies are small, lack blinding, and often use probiotics in combination with other strains or treatments, making it difficult to isolate the effect of L. rhamnosus specifically. Major clinical guidelines currently do not recommend probiotics as a primary therapy for SIBO, but some clinicians may use them as adjuncts based on emerging evidence and their favorable safety profile. Overall, there is scientific interest and some preliminary data, but high-quality, large-scale clinical trials are needed to establish clear efficacy and recommendations.

More about lactobacillus rhamnosus
More about Small Intestinal Bacterial Overgrowth